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Abstract 
In humans, prolonged sedations with propofol or using high doses have been associ-
ated with propofol infusion syndrome. The main objective of this study was to evalu-
ate the effects of prolonged high-dose administration of a specific propofol emulsion 
(Propofol Lipuro) and an improved lipid formulation (SMOFlipid) in liver mitochondrial 
bioenergetics and oxidative stress of rabbits, comparatively to a saline control. Twenty-
one male New Zealand white rabbits were randomly allocated in three groups that 
were continuously treated for 20 h. Each group of seven animals received separately: 
NaCl 0.9 % (saline), SMOFlipid (lipid-based emulsion without propofol) and Lipuro 2 % 
(propofol lipid emulsion). An intravenous propofol bolus of 20 mg kg−1 was given 
to the propofol Lipuro group to allow blind orotracheal intubation and mechani-
cal ventilation. Anesthesia was maintained using infusion rates of: 20, 30, 40, 50 and 
60 mg kg−1 h−1, according to the clinical scale of anesthetic depth and the index of 
consciousness values. The SMOFlipid and saline groups received the same infusion rate 
as the propofol Lipuro group, which were infused during 20 consecutive hours. At the 
end, the animals were euthanized, livers collected and mitochondria isolated by stand-
ard differential centrifugation. Mitochondrial respiration, membrane potential, swell-
ing and oxidative stress were evaluated. Data were processed using one-way ANOVA 
(p < 0.05). The animals revealed a significant decrease in cardiovascular parameters 
showing bradycardia and severe hypotension. No statistical differences were observed 
when using pyruvate as substrate, however, when using succinate as respiratory sub-
strate, significant decrease in ADP-stimulated respiration rate was observed for SMOF-
lipid group (p = 0.002). Lipid peroxides (p < 0.01) and protein carbonyls (p = 0.01) 
showed a statistically significant difference between propofol Lipuro and the SMOFlipid 
groups. These results suggest that lipid-based emulsions can be involved in the regula-
tion of different pathways that ultimately lead to a decrease of state 3 mitochondrial 
respiration rate. The infusion of propofol Lipuro during prolonged periods, in addition 
to marked hypotension and hypoperfusion, also showed to have higher anti-oxidant 
activity and lower impairment of the mitochondrial function comparatively to the 
improved lipid formulation, SMOFlipid, using the rabbit as animal model.
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Background
Propofol is a hypnotic drug largely used through the last decades for both human and 
animal anesthesia and sedation of healthy and critical patients (Li et al. 2012). This small 
lipophilic molecule holds favorable pharmacokinetic and pharmacodynamic proper-
ties as rapid onset, short clinical effect and fast recovery that turn it the choice intra-
venous (IV) drug for continuous infusion for the most diverse procedures (Fodale and 
La Monaca 2008). Nonetheless, adverse side effects were observed when propofol was 
administered in high doses or for long uninterrupted periods to humans, especially, chil-
dren (>4 mg kg−1 h−1; >48 h) (Kam and Cardone 2007; Ahlen et al. 2006; Agrawal et al. 
2013) and rabbits (>20 mg kg−1 h−1; >20 h) (Ypsilantis et al. 2007), indicating the pres-
ence of a complex set of signs and symptoms that owned the name of propofol infu-
sion syndrome (PRIS). The clinical features of PRIS include bradycardia and cardiac 
asystole, hypotension, lipemic plasma, fatty liver, metabolic acidosis and renal failure 
that can lead to death (Kam and Cardone 2007; Vasile et al. 2003; Campos 2010). The 
mechanisms and the physiopathology of this syndrome have not been completely elu-
cidated but in vitro and in vivo studies suggested dysfunction of the mitochondrial res-
piratory chain, impaired fatty acid oxidation and unbalancing energy production (Kam 
and Cardone 2007; Branca et  al. 1991a; Schenkman and Yan 2000; Wolf et  al. 2001). 
Decreased generation and/or maintenance of the transmembrane electrical potential as 
well as reduced cytochrome C oxidase activity have also been reported in the presence 
of propofol (Branca et al. 1991b). Genetic susceptibility to propofol, such as an inher-
ited error of the mitochondrial fatty acid oxidation and polymorphisms in the enzymes 
involved in the propofol metabolism may also play a role (Zaccheo and Bucher 2008). 
The real contribution of propofol to PRIS has been discussed, as it can result from other 
causes (inherent diseases as liver failure or genetic polymorphisms) that also conduct to 
the manifestation of fatal clinical signs that occur while administering propofol or other 
concomitant drugs (Fudickar and Bein 2009). Propofol-sedated rabbits evidenced multi-
organ dysfunction syndrome similar to human PRIS and, recently, propofol-sedated rats 
indicated a possible involvement of coenzyme Q in the physiopathology of PRIS (Ypsi-
lantis et al. 2007; Vanlander et al. 2014). The present study aims to evaluate the in vivo 
effects on hepatic mitochondrial bioenergetics and oxidative stress parameters after a 
long-term high-dose administration of a specific propofol formulation (Propofol Lipuro) 
and an improved lipid emulsion (SMOFlipid) on rabbits.
Methods
Animals
All procedures related to animals were carried out under university ethics committee 
authorization and project license approved by the national regulatory office: Direcção 
Geral de Alimentação e Veterinária (DGAV), protocol No 0420/000/000/2012. All peo-
ple involved in animal procedures had appropriate training following the FELASA rec-
ommendations and were accredited by DGAV. This study was conducted in agreement 
with the national animal welfare laws, guidelines and policies for care and use of experi-
mental animals.
Twenty-one male New Zealand white rabbits, in-house bred and average weight 
2.74  ±  0.21  kg were used. Animals were daily handled from 3  weeks old by the 
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researcher who performed the anesthetic procedure for habituation till approximately 
3 months old, when the experiment was carried out. They were also contained (2 h per 
day) in a standard box during 2 weeks prior to the experiment. Animals were housed 
in proper standard cages, in a room with controlled temperature (20–22 °C), humidity 
(50–60 %), ventilation and light/dark (12/12 h) cycle. Commercial pellet food and water 
were provided ad libitum, with exception to the last 4 h prior to the study. Animal wel-
fare, behavior and clinical signs were periodically assessed before the experimental study 
beginning.
Anesthesia and monitoring
Animals were randomly allocated into three groups, containing seven rabbits each: 
the propofol Lipuro (Propofol Lipuro® 2 %, B. Braun, Germany), the SMOFlipid emul-
sion (SMOFlipid® 20 %, Fresenius Kabi Pharma, Sweden) and the saline (NaCl 0.9 %, B. 
Braun, Germany) group. Monitoring of anesthesia was ensured by Datex S/5 Anesthetic 
station (Datex Ohmeda, Helsinki, Finland) and included cardiorespiratory parameters: 
heart rate (HR), mean arterial blood pressure (MABP), systolic arterial blood pressure 
(SABP), diastolic arterial blood pressure (DABP), end-tidal CO2 (ETCO2), arterial blood 
oxygen saturation (SpO2), respiratory rate (RR) and rectal temperature (T). The evalu-
ation of the anesthetic depth was performed by assessing the main reflexes (palpebral, 
corneal and pedal withdrawal) (Silva et  al. 2011) and by using the IoC-View monitor 
(Aircraft Medical, Barcelona, Spain) to ensure the right level of anesthesia in all ani-
mals. Only the animals of the propofol group were under anesthesia, the animals of 
the SMOFlipid and saline control stayed awake during the entire experiment in proper 
restraining cages so they could adequately receive the intravenous infusion.
After baseline recording in the awake animals during 5 min, the fur on the ears was 
clipped and a local analgesic cream was applied to the ears skin (EMLA, Nycomed US 
Inc, New York, USA). Twenty minutes later, 22G catheters were placed in the marginal 
ear veins (for propofol delivery and blood samples collection) and in the central ear 
arteries (for invasive blood pressure monitoring and samples for blood gases measure-
ments). In the propofol group, the animals were pre-oxygenated with a facial mask at 
5 L min−1 for 5 min. Anesthesia was induced with a 20 mg kg−1 bolus dose of propofol 
Lipuro, using a syringe pump (Asena GH, Alaris Medical Systems, USA) at an infusion 
rate (IR) of 200 ml h−1. Following blind orotracheal intubation with a cuffed endotra-
cheal tube with 2.5  mm internal diameter for mechanical ventilation and 100  % oxy-
gen support, the rabbits were positioned in right recumbence above a heating blanket. 
Mechanical ventilation was performed by pressure (8–10  cmH2O) using Datex S/5 
Anesthetic station (Datex Ohmeda, Helsinki, Finland). The initial settings (respiratory 
rate 20–25  breath  min−1; peak inspiratory pressure 10–12  cmH2O; oxygen flow rate 
1–3 L min−1; positive end-expiratory pressure of 3–5 cmH2O; 1 inspiration: 2 expira-
tions) ensured a tidal volume of 6–8  mL/kg, and these parameters were adjusted to 
maintain a PaCO2 between 35 and 45 mmHg, if required. A deep inspiration (30 cmH2O 
for 1  s) was performed every 2  h, in addition to the applied positive end-expiratory 
pressure (PEEP) to avoid atelectasis. Recumbence was also changed every 4 h. Propo-
fol Lipuro administration started with an infusion rate of 60 mg kg−1 h−1 as tolerance 
to propofol was described in the first 2 h after the onset of the infusion and also due 
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to propofol rapid metabolization and high clearance observed during enzymatic acti-
vation (Campos and al 2015). In each anesthetized animal, the level of anesthesia was 
assured by evaluation of the main reflexes (Silva et al. 2011) and according to the IoC 
values which were maintained between the 50 and 70. Reflexes evaluation was always 
performed at specific time points of the study by the same investigator who was blinded 
to procedures. All infusion rates varied from 20 to 60 mg kg−1 h−1, changed in steps of 
10 mg kg−1 h−1, every time the animals from the propofol Lipuro group showed signs of 
awakening or deepening from anesthesia, so a similar level of anesthetic depth could be 
maintained over time. These doses were defined in agreement with previous data col-
lected from rabbits sedated only with propofol, without pre-medication and for organ 
toxicity and electroencephalographic purposes (Ypsilantis et al. 2007; Silva et al. 2011; 
Campos et al 2015; Martin-Cancho et al. 2006). Adjustments in the infusion rate were 
always performed according to clinical reflexes, IoC values and cardiorespiratory signs. 
Whenever animals showed higher or lighter sedation, the infusion rate was readjusted to 
desired level. Infusion rates started at the same time in all groups, with the SMOFlipid 
and saline groups always receiving the same infusion rate as the propofol Lipuro group. 
Anesthesia was maintained during 20 consecutive hours and vital signs evaluation was 
performed continuously but only recorded every 3 h (T0, T3, T6, T9, T12, T15, T18) 
and at the end (T20), before blood samples collection. At the end of the experiment, the 
animals from the propofol Lipuro group were euthanized by exsanguination under anes-
thesia and the animals from the SMOFlipid and saline groups were sacrificed by cerebral 
concussion followed by exsanguination. Livers from all animals were immediately col-
lected for mitochondria isolation.
Blood and organ samples
Blood samples (2 mL per time-point) were collected in all animals before the infusion 
protocol (baseline data) and every 3 h till the end (T20) for biochemical analysis (serum 
was separated by centrifugation at 3000 rpm for 15 min and stored at −20 °C till analy-
sis), for blood gases measurement and for propofol quantification (arterial blood sam-
ples into heparinized syringes and tubes, respectively). Blood biochemical analysis were 
performed using an ABX Pentra 400 apparatus (Horiba ABX SAS, Montpellier, France) 
and included: hematocrit, total proteins (TP), urea, creatinine, aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), total bili-
rubin (TB), direct bilirubin (DB), alkaline phosphatase (ALP), cholesterol, triglycerides, 
amylase, creatine kinase (CK), glucose, potassium (K+), sodium (Na+), total calcium 
(Ca2+), magnesium (Mg2+), phosphorus and chloride (Cl−).
Arterial blood gases analysis included: pH, PaCO2, PaO2, HCO−3  and oxygen satura-
tion. A blood gas/electrolyte/co-oximetry analyzer (GEM Premier 3000, Bruxelles, Bel-
gium) was used.
Liver, heart, kidney, lungs, skeletal muscle and urinary bladder samples were taken 
from each animal and fixed in 10 % neutral buffered formol-saline solution by immer-
sion and processed for histopathology using routine techniques for paraffin embedding 
and sliced at 3 µm pieces and primarily stained with hematoxylin-eosin (H&E) for histo-
pathological analysis. At the same time, liver was preserved at −80 °C for propofol quan-
tification (Campos and al 2014).
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Propofol quantification in plasma and liver
Propofol concentration at T20 was obtained by gas chromatography/ion trap-mass 
spectrometry (GC/IT-MS) in plasma and liver samples using a GC Varian CP-3800 
(California, USA) equipped with a selective ion trap mass detector (Varian Saturn 4000, 
California USA) using methods previously validated by our group (Campos and al 2014).
Mitochondria isolation
Mitochondria were isolated from rabbit liver by standard differential centrifugation, 
in agreement with standardized methods (Gazzotti et  al. 1997) with few adjustments. 
Briefly, the whole liver was rapidly withdrawn, washed, and homogenized in ice-cold 
homogenization medium [250 mM sucrose, 5 mM HEPES, 0.1 mM EDTA, and 0.1 % 
defatted bovine serum albumin (BSA), pH 7.4]. Tissue and nuclei were separated by cen-
trifugation at 1000×g for 10 min at 4  °C (Sigma 3K-16). Mitochondria were recovered 
from the supernatant by centrifugation at 10,000×g for 10 min at 4 °C. The brown mito-
chondrial pellet was washed twice, re-suspended in respiratory buffer (70 mM sucrose, 
220 mM mannitol, 2 mM HEPES, 0.5 mM EDTA, pH 7.4) and divided in two aliquots, 
one immediately used and the other frozen at −80 °C for further analysis. Total protein 
content of samples was determined by Biuret method (Gornall et al. 1949) using BSA as 
standard.
Mitochondria respiration
Oxygen consumption of isolated liver mitochondria was monitored polarographically 
(Estabrook 1967) with a Clark-type oxygen electrode at 25 °C, in a 1 mL water thermo-
static incubation stirred chamber (CB1-D Hansatech), with constant stirring. The stand-
ard reaction medium consisted of 130 mM sucrose, 50 mM KCl, 5 mM MgCl2, 5 mM 
KH2PO4 and 5 mM HEPES at pH 7.2 on the basis of 1 mg mitochondrial protein per 
1 mL buffer. After a 2 min equilibration period, mitochondria were energized with pyru-
vate–malate (5 mM) or succinate (5 mM) as substrates. Pyruvate–malate indirectly sup-
plies electrons to mitochondrial complex I and succinate directly reduces complex II. 
Rotenone (3 µM) was used to inhibit complex I and avoid reverse flow of electrons from 
complex II to complex I. State 4 respiration corresponds to resting oxygen consump-
tion after phosphorylation of a small amount of ADP. State 3 was started by adding ADP 
(100  nmol  mg  protein−1). Uncoupled respiration was initiated by the addition of car-
bonylcyanide p-trifluoromethoxyphenylhydrazone (FCCP) (1 µg mL−1). The rate of oxy-
gen uptake by mitochondria is expressed as nmol O2 min−1 mg protein−1. Respiratory 
control ratio (RCR) and ADP/O ratios were calculated (Chance and Williams 1956) in 
mitochondria energized with pyruvate–malate and succinate.
Mitochondrial Membrane Potential (ΔΨ)
Mitochondrial transmembrane potential (ΔΨ) was measured by a flourimetric method 
using safranin O dye (Akerman and Wikstrom 1976) and recorded in a Varian Cary 
Eclipse fluorescence spectrophotometer (Varian Inc, Palo Alto, CA, USA) operating at 
485 nm excitation and 586 nm emission at 25  °C. Accumulation of safranine O dye in 
mitochondria is driven by membrane potential and results subsequently in decrease of 
fluorescence. Depolarization results in the release of safranine O dye from mitochondria 
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and subsequent increase of fluorescence. Freshly isolated mitochondria (0.5 mg protein) 
were suspended in 3 mL of a medium (pH 7.4) containing 75 mM sacarose, 50 mM KCl, 
30 mM Tris, 2 mM KH2PO4, 2 mM MgCl2 and 10 μM EGTA in the presence of 5 μM 
safranine O dye supplemented with 1 μg mL−1 rotenone. The formation of membrane 
potential was induced after 2 min equilibration by the addition of 10 mM succinate as 
substrate. Data obtained were calibrated using a K+ gradient (Akerman and Wikstrom 
1976). To this end, safranine O fluorescence was recorded in the presence of 2 nM valin-
omycin and stepwise increasing K+ concentrations (0.2–120 mM) which allowed calcu-
lation of ΔΨ by the Nernst equation assuming a matrix K+ = 150 mm (Akerman and 
Wikstrom 1976). No correction for bound safranine O dye was applied because titra-
tion of the fluorescence signal with the dye in buffer without or with sample resulted in 
undistinguishable calibration curves.
Mitochondrial swelling
Swelling of isolated mitochondria was measured by absorbance changes at 540 nm on a 
Varian 50 spectrophotometer (Varian Inc, Palo Alto, CA, USA), in a thermostatic cham-
ber with magnetic stirring at 30  °C according to Oliveira et  al. (2001). Briefly, 0.5  mg 
mitochondrial protein was added to 2  mL of medium containing 135  mM potassium 
acetate, 5 mM HEPES (pH 7.2), 0.1 mM EGTA, and 0.2 mM EDTA supplemented with 
2 μM rotenone. All assays were performed in the presence of 1 μg/mL valinomycin to 
increase permeability to potassium. A control assay was performed in the presence of 
1 μM FCCP as a calibration standard to cause maximal swelling.
Mitochondrial respiratory chain complex activities
Aliquots of mitochondrial suspensions were submitted to three cycles of freezing–thaw-
ing in order to disrupt intact mitochondria and measures were started by the addition 
of 10  μg of mitochondrial protein on a temperature controlled (30  °C) Biotek Power 
Wave XS2 well plate reader (Bio-Tek Instruments, Winooski, VT, USA) according to 
previously established methods (Kiebish et  al. 2008). Complex I (NADH: ubiquinone 
oxidoreductase) activity was monitored following the oxidation of NADH at 340  nm 
(ε =  6220  M−1  cm−1) in a medium containing 50  mM potassium phosphate, pH 7.4, 
2 mM KCN, 5 mM MgCl2, 2.5 mg mL−1 BSA, 0.03 mM antimycin, 0.1 mM decylubiqui-
none and 0.3  mM NADH. Only the rotenone sensitive activity was considered. Com-
plex II (succinate dehydrogenase) activity was monitored at 600  nm by following the 
reduction of 6,6-dichlorophenolindophenol (DCPIP) (ε = 19,100 M−1 cm−1) in a buffer 
containing 50 mM potassium phosphate, pH 7.4, 20 mM succinate, 2 mM KCN, 50 μM 
DCPIP, 0.025  mM rotenone, and 0.03  mM antimycin. Only the oxaloacetate sensitive 
rate was considered. Complex III (cytochrome bc1 complex) activity was monitored at 
550 nm by following the ubiquinol reduction of cytochrome c (ε = 18,500 M−1 cm−1) 
in a buffer containing 5 mM potassium phosphate, pH 7.4, 1 mM EDTA, 1 mM KCN, 
0.1 % tryton X-100, 32 μM oxidized cytochrome c and 35 μM decylubiquinol, prepared 
according to Luo et al. (2008). Only the antimycin sensitive rate was considered. Com-
plex IV (cytochrome c oxidase) activity was determined at 550  nm by measuring the 
oxidation of reduced ferrocytochrome c (ε = 18,500 M−1 cm−1), prepared according to 
Trounce et al. (1996), in a buffer containing 10 mM Tris–HCl and 120 mM KCl, pH 7.0. 
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Only the cyanide sensitive rate was considered. Activities were normalized to citrate 
synthase activity which was performed at 412 nm following the reduction of 5,5′-dithio-
bis(2-nitrobenzoic acid) (ε =  13,600  M−1  cm−1) in a buffer containing 200  mM Tris–
HCl, pH 8.0, 0.01 mM DTNB, 0.02 % Triton X-100, 1 mM oxaloacetate and 0.37 mM 
Acetil-CoA (Monteiro-Cardoso et al. 2015).
Hepatic oxidative stress assay
The enzymatic and non-enzymatic antioxidant activities were measured at 25 °C in the 
hepatic cytosolic fraction from all groups considered in this study. Livers were homog-
enized in ice-cold potassium phosphate buffer 50  mM, pH 7.0. The fractions were 
obtained after centrifugation at 16,000×g for 20 min at 4 °C (Sigma 3K-16). Superoxide 
dismutase (SOD) activity was assayed by measuring its ability to inhibit the photochemi-
cal reduction of nitrobluetetrazolium (NBT) at 560 nm (Paya et al. 1992), in the presence 
of 100 mM potassium phosphate buffer (pH 7.8), 10 mM EDTA, 10 mM NBT, 10 mM 
hypoxanthine and 0.023 U mol−1 xanthine oxidase. One unit of SOD was defined as the 
enzyme activity that inhibited the photo-reduction of NBT to blue formazan by 50 %. 
Catalase (CAT) activity was evaluated following oxygen production in the system using 
a Clark’s oxygen electrode (Del Rio et  al. 1977) in a 50 mM sodium phosphate buffer 
(pH 7.0) containing 1  M H2O2. CAT activity was expressed in terms of micromoles 
H2O2 consumed per minute per milligram protein. Both GSH and GSSG, glutathione in 
reduced and oxidized states respectively, were measured fluorometrically using the fluo-
rochrome ortho-phthalaldehyde (OPA) (1 mg mL−1 methanol) at 350 and 420 nm exci-
tation and emission wavelengths, respectively (Hissin and Hilf 1976). To measure GSH 
content, samples were incubated at room temperature in a buffer containing 100 mM 
potassium phosphate buffer (pH 8.0), 5  mM EDTA and 20  μL OPA. To determinate 
GSSG content, samples were first incubated at room temperature with 0.04 M of N-eth-
ylmaleimide (NEM) for 30 min and then incubated in a medium containing 0.1 N NaOH 
(pH 12.0) and 20 μL OPA. Concentrations were calculated using standard curves pre-
pared with different concentrations of GSH and GSSG and expressed as their ratio. The 
lipid peroxidation (LPO) was evaluated in terms of thiobarbituric acid reactive substance 
(TBARS) formation (Ottolenghi 1959). The data is expressed as nmol MDA formed per 
milligram protein using molar extinction coefficient of 1.56  ×   10 M−1 cm−1. The esti-
mation of lipid hydroperoxides was assayed by the method of Jiang et al. (1992). Protein 
carbonyls were measured using the method of Reznick and Packer (1994) by reaction 
with 10 mM 2,4-dinitrophenylhydrazine (DNPH). ROS generation was measured in liver 
samples according to a method already described in literature (Monteiro-Cardoso et al. 
2015). Total protein content of samples was determined by Biuret method (Gornall et al. 
1949) using BSA as standard.
Statistical analysis
Animal sample size was calculated using a statistical power test with a power above 80 % 
and α = 0.05, where mean and standard deviation information for the different variables 
were obtained from previous works with rabbits (Campos 2010; Silva et al. 2011). Data 
was imported to GraphPad Prism® software (GraphPad Software, version 6.0, Inc., San 
Diego, CA, USA). A Shapiro–Wilk test was used to evaluate data normality. Clinical and 
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mitochondria data that follow normal distribution are showed as mean ± standard devi-
ation (M ± SD) and whereas results from non-parametric data are showed as median 
and interquartile range. To assess the variability from cardiorespiratory data and blood 
biochemical analysis, statistical comparisons were performed between the defined study 
times (T0–T20) using analysis of variance (ANOVA) for repeated measures with the 
Tukey’s correction for normal data and the Friedman test with Dunn’s post hoc for non-
parametric data. Statistical significance between groups for mitochondria sample analy-
sis was determined using one-way ANOVA followed by Tukey’s or the Kruskal–Wallis’ 
followed by Dunn’s multiple comparison tests, according to data normality. For all analy-
ses, values of p < 0.05 were considered significant.
Results
Clinical parameters and propofol concentration
All anesthetized animals survived the 20 h of continuous anesthesia. The mean infusion 
rate of propofol was 37.6 ± 18.1 mg kg−1 h−1 and the first evidences of collapsing were 
observed at 12 ±  2.4  h after the infusion onset and included significant variations in 
cardiorespiratory signs (Table 1) and in blood biochemistry measurements in the propo-
fol Lipuro group (Additional file 1: Table S1). Changes in cardiorespiratory parameters 
were essentially noticed after 12  h of propofol Lipuro administration. Heart rate and 
blood pressure were the variables that showed significant variations during the anes-
thetic period, particularly, after 12  h of infusion. Hypotension was marked in the end 
of the infusion protocol (T20) and was accompanied by an increase in heart rate, how-
ever, only slight drops in pH, HCO−3, T °C and SpO2 were noticed, with an increase in 
PaCO2 within the physiological limits. Clinical signs were also monitored in the saline 
and SMOFlipid groups and deviations from the normal ranges of each parameter were 
not observed.
Concerning blood biochemistry, changes between blood parameters were observed 
at different time-points in the propofol Lipuro and SMOFlipid emulsion groups. In 
the saline group, no differences were found during the entire study. A large number of 
parameters (ALP, cholesterol, glucose, triglycerides, CK, Na+) exhibited statistical differ-
ences from T12 after the onset of propofol Lipuro and SMOFlipid administration till the 
end of the infusion. From a general overview of each group, the propofol Lipuro group 
was the one that showed more significant differences among the parameters in study 
during the 20 h protocol. Table 2 shows the comparison between groups made at spe-
cific time-points for blood biochemistry parameters, statistical differences are observed 
not only between the saline and the propofol Lipuro group but also between the saline 
and SMOFlipid and the SMOFlipid and the propofol Lipuro group. At the end (T20) the 
mean propofol concentration was 52.08 ± 15.65 μg mL−1 in plasma whereas in the liver 
was 2.98 ± 0.69 μg g−1.
Histopathological report
Histopathological results showed that microscopic cardiac lesions were absent in ani-
mals from saline and SMOFlipid groups, however, in the propofol Lipuro group, myo-
cardial vacuolar degeneration, focal necrosis and myocarditis were observed. Occasional 
hepatic cellular tumefaction or mild microvacuolar/hydropic degeneration was present 
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Table 2 Blood biochemistry differences (Mean ±  SD, n =  7) between  the study groups 
(saline, SMOFlipid and propofol Lipuro) obtained from 12 to the 20 h of drug infusion
Parameter Saline SMOFlipid Propofol Lipuro
12 h sampling
 ALP 144.8 ± 27.0a 315.7 ± 32.6b 198.7 ± 46.6c
 ALT 23,6 ± 9.6a 75.9 ± 25.7b 46.4 ± 15.5c
 AST 20.8 ± 6.4a 68.8 ± 21.5b 38.3 ± 25.1a
 Glucose 106.6 ± 15.1a 135.2 ± 24.4b 124.1 ± 14.5a,b
 Cholesterol 29.0 ± 5.1a 73.1 ± 43.5b 106.6 ± 16.9c
 Triglycerides 55.2 ± 12.8a 922.1 ± 194.3b 768.6 ± 124.7b
 LDH 140.6 ± 33.7a 671.9 ± 358.8b 588.9 ± 285.2b
 CK 1149.5 ± 261.3a 4898.0 ± 214.1b 1278.7 ± 368.8c
 Amylase 302.8 ± 35.6a 374.6 ± 91.4a 449.9 ± 87.9b
 Urea 28.4 ± 8.5a 26.4 ± 4.6a 69.5 ± 18.7b
 Creatinine 0.9 ± 0.7a 1.0 ± 0.3a 2.9 ± 0.4b
 Phosphorus 4.3 ± 1.0a 7.8 ± 3.2b 10.7 ± 3.8b
 Ca2+ 11.7 ± 0.8a,b 12.5 ± 3.5a 9.7 ± 1.2b
 Na+ 129.9 ± 12.1a 145.3 ± 12.3b 140.4 ± 5.9a,b
15 h sampling
 ALP 148.0 ± 16.1a 255.4 ± 44.1b 171.8 ± 48.7a
 ALT 27.0 ± 8.6a 65.6 ± 34.9b 45.3 ± 13.7a
 AST 25.5 ± 4.8a 42.3 ± 27.1a 88.7 ± 29.1b
 Glucose 105.5 ± 8.9a 134.3 ± 18.1b 126.1 ± 15.7a,b
 Cholesterol 36.6 ± 6.4a 79.8 ± 37.4b 122.5 ± 14.8c
 Triglycerides 61.8 ± 26.8a 1066.7 ± 203.1b 1022.7 ± 94.2b
 LDH 142.8 ± 39.4a 730.3 ± 366.2b 587.7 ± 181.1b
 CK 1122.8 ± 172.8a 7225.4 ± 863.7b 1840.0 ± 390.7c
 Amylase 326.6 ± 51.1a 371.6 ± 88.2a 459.9 ± 101.6b
 Urea 25.5 ± 7.1a 28.7 ± 7.1a 82.2 ± 13.3b
 Creatinine 1.2 ± 0.4a 1.3 ± 0.3a 3.4 ± 0.5b
 Phosphorus 4.2 ± 0.8a 8.6 ± 2.8b 11.8 ± 5.5c
 Ca2+ 11.8 ± 0.7a 1.4 ± 2.5a 9.7 ± 2.1a
 Na+ 139.2 ± 10.2a 144.2 ± 4.4a 140.6 ± 7.8a
18 h sampling
 ALP 132.2 ± 21.8a 260.1 ± 49.8b 173.8 ± 44.2a
 ALT 23.0 ± 12.9a 58.4 ± 22.1b 56.1 ± 15.8a
 AST 19 ± 4.7a 33.0 ± 18.5a 100.4 ± 18.6b
 Glucose 101.8 ± 12.2a 120.4 ± 26.1a 127.6 ± 20.8a
 Cholesterol 30.7 ± 6.2a 82.1 ± 58.5b 131.3 ± 27.8c
 Triglycerides 73.6 ± 26.9a 1608.5 ± 226.2b 1119.6 ± 112.3c
 LDH 158.5 ± 51.2a 879.6 ± 373.7b 602.5 ± 331.4c
 CK 1113.4 ± 468.6a 6584.5 ± 542.1b 2063.1 ± 495.5c
 Amylase 369.5 ± 32.1a 586.2 ± 101.4b 513.7 ± 138.2b
 Urea 26.4 ± 6.4a 18.9 ± 3.3a 95.3 ± 10.0b
 Creatinine 0.9 ± 0.6a 1.2 ± 0.4a 3.7 ± 0.4b
 Phosphorus 3.9 ± 0.6a 9.1 ± 3.2b 11.9 ± 7.4b
 Ca2+ 12.1 ± 1.9a 11.1 ± 3.1a 9.6 ± 1.9a
 Na+ 139.6 ± 9.5a 143.3 ± 9.5a 139.2 ± 6.9a
20 h sampling
 ALP 135.8 ± 16.4a 273.8 ± 47.2b 189 ± 52.7c
 ALT 25,3 ± 11.4a 73.6 ± 26.2b 48.0 ± 18.0c
 AST 29.2 ± 13.2a 47.6 ± 17.4a 140.0 ± 24.2b
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in animals from the saline and propofol Lipuro groups, which was focal and without 
pathological significance. In this last group, single cell necrosis, as well as multifocal hep-
atitis with heterophils and occasional lymphocytes were also present. The animals from 
the SMOFlipid group displayed hepatic lesions of massive hydropic degeneration, con-
sistent with generalized steatosis (Fig. 1). Microscopic examination of the lungs from the 
propofol Lipuro and SMOFlipid groups revealed atelectasis and arterial vascular lesions, 
which included sub-endothelial vasculitis with heterophils and some eosinophils, inti-
mal hyperplasia and degenerative changes of the muscle cells in the medial arterial wall. 
In some of the animals from the propofol Lipuro and SMOFlipid groups these vascular 
changes were accompanied by fragmentation of the internal elastic membrane. Animals 
from these two groups also presented sparse interstitial lymphocytic inflammation, as 
well as an increased number of alveolar macrophages. With the exception of animals 
from the propofol Lipuro group, which had microscopic changes consistent with pro-
teinuria and acute renal failure, no significant renal changes were observed in the other 
groups (SMOFlipid and saline). Skeletal muscle and urinary bladder microscopic obser-
vation revealed no significant lesions in all the animals from the three groups under 
study.
Different letters show significant differences between study groups (p < 0.05)
Table 2 continued
Parameter Saline SMOFlipid Propofol Lipuro
 Glucose 99.8 ± 13.1a 147.6 ± 17.9b 125.8 ± 14.3a,b
 Cholesterol 30.2 ± 7.6a 87.6 ± 57.4b 138.7 ± 48.9c
 Triglycerides 66.1 ± 15.8a 1685.4 ± 103.4b 1086.8 ± 254.1c
 LDH 155.2 ± 56.7a 750.0 ± 256.2b 607.0 ± 272.4b
 CK 1035.8 ± 385.2a 10,492.0 ± 874.3b 3988.8 ± 657.6c
 Amylase 336.2 ± 27.9a 668.9 ± 112.4b 502.7 ± 112.3c
 Urea 26.7 ± 4.2a 23.2 ± 5.5a 89.7 ± 15.2b
 Creatinine 1.03 ± 0.4a 1.1 ± 0.3a 3.9 ± 0.7b
 Phosphorus 4.3 ± 0.9a 9.7 ± 4.6b 12.4 ± 3.1b
 Ca2+ 11.7 ± 1.7a 12.4 ± 4.0a 9.9 ± 2.6a
 Na+ 130.5 ± 14.2a 137.5 ± 5.4a 139.4 ± 5.8a
Fig. 1 Microscopic images (H&E) of liver from animals of each study group (propofol Lipuro, SMOFlipid and 
saline) at the end of the 20 h of treatment. Liver changes in animals from the saline and propofol groups 
were similar and characterized by occasional hepatic cellular tumefaction or mild microvacuolar/hydropic 
degeneration. In the SMOFlipid group, hepatic lesions of massive hydropic degeneration, consistent with 
generalized steatosis. The majority of animals tested had no microscopic cardiac lesions, however myocardial 
vacuolar degeneration, focal necrosis and myocarditis were observed in the propofol group (scale bar 50 µm)
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Effects on mitochondria respiratory chain function and mitochondrial coupling
The respiratory activity of isolated liver mitochondria was measured using two differ-
ent substrates, namely, pyruvate-malate and succinate and the results are presented in 
Table  3. The state 3 and 4, reflecting ADP-stimulated and ADP-absence respiration, 
respectively, showed no significant differences when complex I substrate was used. 
However, when using succinate as respiratory substrate, a distinct trend to decrease in 
ADP-stimulated respiration rate was observed for the SMOFlipid group (p =  0.0005) 
compared to control group. The coupling between respiration and phosphoryla-
tion (RCR) and the ratio of ADP molecules phosphorylated to oxygen atoms reduced 
(ADP/O) was not significantly affected in all groups when both substrates were used. 
Also, no differences were observed in the mitochondrial membrane potential when suc-
cinate was used, indicating that respiratory coupling and electron transport chain func-
tion were not significantly affected. Furthermore, no statistical differences between 
groups were observed in mitochondrial swelling, which was confirmed using the oxida-
tive phosphorylation uncoupler FCCP (Fig. 2). 
Table 3 Results from  respiratory chain activity when  different substrates obtained 
from  different mitochondrial preparations for  each experimental group energized 
with pyruvate-malate or succinate (5 mM)
Results expressed by M ± SD (mean ± standard deviation) or median and interquartile range for liver mitochondria 
(1 mg mL−1 of protein). Oxidative phosphorylation was measured polarographically at 25 °C in 1 mL. ΔΨ was measured 
using a TPP+-selective electrode at 25 °C in a total volume of 1 mL. Different letters show significant differences between 
groups (p < 0.05)
Parameter Group Statistical 
test
p
Saline SMOFlipid Propofol Lipuro
Pyruvate-malate substrate
 State 3 rate  
(nmol O2 min
−1 mg  
protein−1)
54.66 ± 16.97 47.81 ± 18.04 41.07 ± 15.04 F(2,17) = 1.67 0.34
 State 4 rate  
(nmol O2 min
−1 mg  
protein−1)
16.82 [13.58–19.60] 20.06 [14.24–28.35] 15.48 [11.23–20.77] χ2(2) = 1.29 0.52
 Uncoupled rate  
(nmol O2 min
−1 mg  
protein−1)
44.59 ± 17.08 47.99 ± 18.36 50.25 ± 17.99 F(2,17) = 0.18 0.84
 RCR 2.48 [2.20–3.11] 2.34 [1.92–2.91] 2.81 [2.34–3.12] χ2(2) = 3.08 0.21
 ADP/O 2.60 ± [2.34–2.94] 2.85 [2.79–2.91] 2.64 [2.37–2.97] χ2(2) = 0.72 0.69
Succinate substrate
 State 3 rate  
(nmol O2 min
−1 mg  
protein−1)
51.68 ± 3.42a 38.42 ± 4.15b 45.66 ± 7.29a,b F(2,18) = 9.13 0.002
 State 4 rate  
(nmol O2 min
−1 mg  
protein−1)
22.99 ± 4.26 20.63 ± 5.83 21.34 ± 3.37 F(2,20) = 2.84 0.09
 Uncoupled rate  
(nmol O2 min
−1 mg  
protein−1)
177.5 ± 39.4 141.8 ± 35.47 166.8 ± 23.06 F(2,18) = 3.05 0.08
 RCR ou ICR 2.40 ± 0.17 2.06 ± 0.10 2.16 ± 0.12 F(2,18) = 1.59 0.23
 ADP/O 1.34 ± 0.40 1.33 ± 0.39 1.33 ± 0.35 F(2,19) = 0.15 0.86
 Membrane potential 171.7 ± 30.15 145.8 ± 37.5 156.8 ± 26.1 F(2,20) = 1.18 0.33
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Effects on mitochondria respiratory chain complexes activities
The enzymatic activity of the mitochondrial respiratory chain complexes I, I–III, II, II–
III, III and IV were determined by spectrophotometric methods and normalized to the 
citrate synthase activity, which was similar between groups, and are displayed in Table 4. 
Despite a slight decrease, but not statistically significant (30 %), in the enzyme activity of 
complex IV in the propofol Lipuro group, no other significant differences in the specific 
activities of all other mitochondrial complexes were found.
Effects of propofol on oxidative stress
Figure  3 shows the effects of propofol Lipuro and SMOFlipid emulsion on the activi-
ties of enzymatic and non-enzymatic antioxidants. Despite a slight increase in SOD 
activity for SMOFlipid and propofol Lipuro groups, no statistical significant differ-
ences were observed between groups. Similarly, the analysis of CAT and GPx showed 
no significant differences between groups, even though lower values were observed 
for the SMOFlipid and propofol Lipuro groups. The redox status of the cell, meas-


















Fig. 2 Mitochondrial swelling results observed in all three groups (propofol Lipuro, SMOFlipid and saline). 
The control experiment was made in the absence of carbonylcyanide p-trifluoromethoxyphenylhydrazone 
(FCCP) and propofol. Maximum swelling was obtained with FCCP (1 mM). Valinomycin (1 mM) was added 
after 1 min. The traces are representative of a group of at least three independent experiments
Table 4 Propofol effects on liver mitochondrial respiratory chain activities after the 20 h 
infusion in the 3 groups
Results expressed by M ± SD (mean ± standard deviation) or median and interquartile range for liver mitochondria (10 μg 
of protein) obtained from different mitochondrial preparations for each experimental group. No statistical significance was 
observed between groups
Activity Group Statistical test p
Saline SMOFlipid Propofol Lipuro
Complex I 4.43 ± 2.33 4.08 ± 0.98 3.60 ± 1.54 F(2,17) = 0.35 0.71
Complex I–III 13.63 ± 5.76 14.44 ± 2.29 13.07 ± 4.32 F(2,17) = 0.15 0.86
Complex II 0.19 ± 0.11 0.14 ± 0.08 0.25 ± 0.11 F(2,17) = 0.68 0.52
Complex II–III 5.01 ± 2.33 4.14 ± 1.54 4.54 ± 1.96 χ2(2) = 0.13 0.94
Complex III 2.11 ± 1.64 2.06 ± 0.57 1.68 ± 0.71 χ2(2) = 0.72 0.69
Complex IV 14.81 ± 9.48 16.34 ± 7.56 10.25 ± 7.79 χ2(2) = 5.54 0.06
Citrate synthase 2.26 ± 1.09 1.56 ± 0.34 2.10 ± 0.63 F(2,17) = 1.43 0.27
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increase with the administration of propofol Lipuro and the SMOFlipid emulsion. Lipid 
peroxides showed a statistically significant difference between propofol Lipuro and 
saline (p < 0.0001) and SMOFlipid (p < 0.0001) groups. A similar profile was observed 
Fig. 3 Effects of Propofol Lipuro and the SMOFlipid emulsion on the activities of enzymatic and non-enzy-
matic antioxidants obtained from different mitochondrial preparations for each experimental group, at the 
end of the infusion time (T20). Asterisks indicates statistical significance between study groups (p < 0.05)
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for propofol hydroperoxides (p  =  0.03) when compared to the saline control group. 
Between the SMOFlipid and control group no differences were observed. Protein car-
bonyls only reflected a significant difference between propofol Lipuro and the SMOF-
lipid (p = 0.009) group. The effect of propofol Lipuro and SMOFlipid treatment on ROS 
production was also evaluated and no statistical differences were observed between 
groups, despite a slight decrease (37 %) for propofol Lipuro group.
Discussion
Propofol infusion syndrome (PRIS) has been extensively described in the last decade 
in humans, mostly in critically ill children and intensive care adult patients undergoing 
long-term sedation at high doses of propofol (Fodale and La Monaca 2008; Kam and 
Cardone 2007; Ahlen et  al. 2006; Vasile et  al. 2003; Fudickar and Bein 2009). In  vivo 
studies were conducted by Yspilantis et  al. (2007), where New Zealand rabbits were 
continuously sedated for 32.3 ±  5.4 h with propofol and after 20 h of anesthesia they 
showed blood biochemical and histological changes in the main organs resembling 
PRIS (Ypsilantis et al. 2007). In our study, all animals survived the 20 h anesthesia with a 
mean infusion rate of propofol was 37.6 ± 18.1 mg kg−1 h−1. Clinical and hemodynamic 
changes were noticed 12  h after the propofol infusion start. Sedated animals showed 
progressive variations in clinical parameters and blood biomarkers during the moni-
toring period, conducting to a characteristic set of signs that resemble human PRIS. 
Although the doses used in our study were high comparatively to that used in humans, 
the doses used were just to maintain the animals in a sedated level of anesthesia, as it 
was showed by the IoC values, that were never lower than 60, indicating that no over-
doses were reached. Ypsilantis and colleagues (2007) anesthetized three groups of rab-
bits: one continuously infused with propofol (initial infusion rate of 20  mg  kg−1  h−1 
increased up to 65.7 mg kg−1 h−1 for maximum period of 38 h where animals died by 
themselves), another with sevoflurane (ranging from 1.5–4 %) and one last with sevo-
flurane and intravenous Intralipid 10 %, all under mechanical ventilation. The amount 
of Intralipid delivered to animals was not specified in the Ypsilantis’ study. Changes in 
hepatic biomarkers and histologic lesions in liver, kidneys and lungs were observed in 
the propofol and Intralipid groups, indicating that propofol lipid emulsion can also be 
responsible for part of this syndrome (PRIS) (Ypsilantis et  al. 2007). In our study, we 
evaluated the effects of a 20 h prolonged high-dose administration of propofol Lipuro 
and an improved lipid emulsion as SMOFlipid, separately administered to rabbits 
(Adolph et al. 2009), on liver mitochondrial bioenergetics and oxidative stress without 
the use of other concomitant anesthetics, without the presence of confounding varia-
bles, as other anesthetics.
Clinical signs monitored in the propofol Lipuro group showed bradycardia followed 
by reflexive tachycardia due to hypotension. Progressive decreases in HCO−
3
 concen-
tration in arterial blood and pH suggest the development of metabolic acidosis mainly 
due to hypoxia and hypoperfusion with progressive failure of the heart and kidneys 
caused by propofol prolonged infusion and its accumulation in tissues (Ypsilantis 
et  al. 2007; Campos et  al. 2015). Although the lactate values were not monitored, the 
increase of the Cl− concentration in the final hours seems to compensate the low HCO−
3
 
(Fudickar and Bein 2009). Several studies suggest that the mechanisms of hypotension 
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are propofol-mediated decreases in sympathetic activity including decrease in cardiac 
output due to venous and arterial vasodilatation, impaired baroreflex mechanism and 
depression of myocardial contractility (Robinson et  al. 1997). Our study showed that 
the sympathoinhibitory effects of propofol particularly observed near the end of the 
study by the severe cardiovascular depression, contributed importantly to the hemody-
namic consequences of propofol Lipuro anesthesia and driven to the results obtained 
for mitochondrial function and oxidative stress. This can be associated to an accumu-
lation of propofol during prolonged infusions caused by the saturation of the meta-
bolic enzymatic system (Campos et  al. 2015). Indeed, according to, Chang et  al. 2001 
a significant decreased membrane potential and distorted mitochondria morphology of 
aortic endothelial cells mean that the clinical hypotension induced by propofol might 
be a potential mechanism (Chang et al. 2001). Histological analysis confirmed the pres-
ence of multi-organic lesions consistent with PRIS as: liver failure and steatosis, heart 
inflammation and renal failure (Ypsilantis et  al. 2007; Fudickar and Bein 2009). These 
results together with changes observed in clinical signs, gas measurements and blood 
biomarkers (liver, renal and lipid ones), suggest that the animals under propofol Lipuro 
sedation developed signs compatible with PRIS after 20 h of infusion. Moreover, some 
clinical parameters in the SMOFlipid group such as serum lipids, liver enzymes, CK and 
sodium, revealed to be statistically different not only from the saline but also from the 
propofol Lipuro group while biomarkers as urea, creatinine and amylase did not change 
along time in the SMOFlipid group, evidencing that these animals did not develop renal 
or pancreatic lesions. The increase of the CK levels may result from heart and renal fail-
ure/inflammation and/or incipient rhabdomyolysis. Similar changes in cardiac function 
during anesthesia have been described in human patients with PRIS (Kam and Cardone 
2007; Bray 1998). A progressive bradycardia was noticed until 15 h of propofol Lipuro 
infusion followed by evident tachycardia, possibly reflex to hypotension observed after 
this period (Martin-Cancho et  al. 2006). Histologic examination revealed myocarditis 
and smooth degeneration consistent with myofibril degeneration or rhabdomyolysis, 
however, the absence of ECG monitoring did not allow the identification of asystole in 
animals around the 20  h of anesthesia. Kidney biomarkers in blood (urea, creatinine, 
CK) were above the maximum limit, indicating late injury and failure. This was also 
confirmed by microscopy that revealed nephritis and proteinuria. Long-term propofol 
administration is also related with variations in pancreatic enzymes, especially in chil-
dren. The high levels of amylase in the propofol group in end of the study, together with 
the high levels of triglycerides, suggests an early pancreatic inflammation (Gottschling 
et al. 2005) but no histologic examination was performed to the pancreas.
Hepatomegaly, hypertriglyceridemia and cholestatic liver have been associated 
with high lipid load and therapeutic failure during long-term propofol administration 
(Adolph et al. 2009; Knibbe et al. 2004) and were observed in the propofol Lipuro and 
the SMOFlipid groups. Fatty acids are metabolized in many tissues including hepato-
cytes, myocardium and muscles. Clinical, in vitro and in vivo studies pointed that lipid 
infusions may induce not only immunosuppressive effects (Adolph et  al. 2009; Cal-
der et al. 2002) but also impaired fat metabolism (Lindholm 1992). A continuous lipid 
administration that exceeds the rate of oxidation can evolve to a ‘Fat overload syndrome’ 
(FOS). Excess lipid particles are up taken by immune cells (mononuclear phagocytes 
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generating immunodeficiency, known by systemic inflammatory response syndrome 
(SIRS) (Adolph et al. 2009; Palmblad 1991). Curiously, FOS, SIRS and PRIS have similar 
clinical manifestations: hepatomegaly, increased serum lipids, metabolic acidosis among 
others. In addition, cells membranes contain fatty acids that can affect numerous mem-
brane properties as fluidity, transport processes, the activity of membrane proteins and 
receptors and also modify gene expression by binding to nuclear receptors (Adolph et al. 
2009). While propofol formulations are prepared in lipid vehicles, its use during long-
term anesthesia and sedation, increases the probability of PRIS occurrence. PRIS results 
from side-effects of propofol over non-targeted organs (like heart, lungs and kidneys) 
associated to prolonged lipid emulsion infusions. This may be also potentiated by the 
genetic susceptibility of each individual to metabolize xenobiotics (Kneiseler et al. 2010). 
The non-monitoring of serum lipids in patients receiving lipid-containing propofol infu-
sions, frequently leads to an excess of triglycerides which can be a limiting factor for 
propofol dosing and therapeutic management (Knibbe et al. 2004; Kobayashi et al. 2008). 
In our study, the lipid formulations used (propofol Lipuro vs SMOFlipid emulsion) had 
different types of triglycerides (soya-bean vs. fish-oil based). SMOFlipid emulsion was 
chosen for lipid infusion due to its improved composition (by containing other oils than 
soya-bean) and lower incidence of side effects (multi-organ damage) compared with 
other vehicles (Koller et  al. 2003), even so, many undesired changes were observed in 
our study. Notwithstanding, the clinical and scientific popularity achieved with paren-
teral nutrition or propofol emulsions challenged the discovery of new lipid-based for-
mulations (Knibbe et al. 2004; Jung et al. 2010).
Several studies describe the pathophysiology of PRIS as an imbalance of the mitochon-
drial respiratory chain, leading to disruption on cellular energy production and, conse-
quently, compromising Krebs cycle, metabolism of amino acids and fatty acid oxidation 
and consecutive cell death (Vasile et al. 2003; Kneiseler et al. 2010; Muravchick and Levy 
2006). In fact, many in vitro and in vivo studies have reported relevant injury to the heart 
(Argaud et al. 2008; Shao et al. 2008), brain (Kiebish et al. 2008; Marian et al. 1997) and 
liver (Branca et al. 1991a, b; Rigoulet et al. 1996) mitochondria as a consequence of high 
propofol concentrations resulting in an impairment oxygen utilization and ATP pro-
duction and decreased electron flow (Schenkman and Yan 2000; Muravchick and Levy 
2006; Marian et al. 1997). Propofol also affects mitochondrial at complex I level as well 
as uncouples oxidative phosphorylation. It is also thought to interfere with complex II 
(Wolf et al. 2001), however, few studies have focused on the in vivo mitochondrial effects 
of propofol. In our work, we have determined respiratory function of liver mitochon-
dria. Surprisingly, when using succinate as respiratory substrate for complex II, a sig-
nificant decrease in ADP-stimulated respiration rate was observed for the SMOFlipid 
group, suggesting that the lipid emulsion inhibited the state-3 oxygen consumption rate, 
corresponding to the mitochondrial capacity to synthetize ATP, and revealing poor effi-
ciency of proton-pumping activity and consequent decrease of the respiratory rate from 
this electron donor. This effect was observed in isolated rat liver mitochondria, when 
a subclinical dose of propofol was added to in  vitro to a specific amount of isolation 
medium (Rigoulet et al. 1996). However, and despite the observed result for state-3 res-
piration, the analysis of the mitochondrial membrane potential showed no significant 
effects despite a slight decrease for the SMOFlipid group. The same was confirmed by 
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the analysis of mitochondrial swelling indicating that the mitochondrial membrane was 
not affected by the treatments and thus preserving the mitochondrial function con-
versely to what was found by Wu et al. (2005). In fact, this is not the first time that this 
effect is documented for propofol (Adembri et al. 2006).
Additionally, the mitochondrial inner membrane lipid composition is of importance 
for the stabilization of the respiratory chain complexes (Zigdon et al. 2013) within which 
complex I and III have been identified as the major sources of ROS. In this study, con-
trarily to what was found by Vanlander et  al. (2014), no significant differences were 
observed neither for succinate cytochrome c reductase (complex II + III) nor for com-
plex II as observed by Kajimoto (2014). In fact, we have only observed a tendency to 
decrease complex IV activity which is regulated by the mitochondrial electric membrane 
potential modulating the activity of the ETC according to its needs (Desler et al. 2012). 
The importance of this complex for the optimal activities of complex I and III has been 
previously demonstrated (Schafer et  al. 2006). Furthermore, as complex IV is particu-
larly sensitive to changes in the fluidity of the membrane lipid composition (Trivedi 
et al. 1986), we can assume that our results are most likely due to propofol interaction 
with the membrane. In fact, it has been already described the ability of propofol to inter-
act and change the membrane fluidity at clinically relevant concentrations (Bahri et al. 
2007). This could be explained by an incorporation of propofol into the inner mitochon-
drial membrane and prevention of the opening of the MPTP which was already been 
observed in other studies (Adembri et al. 2006; Shirakawa et al. 2014).
Many studies have already showed the antioxidant capacity of propofol (Mathy-Har-
tert et al. 1998) which may be resultant from its α-tocopherol similar structure. In our 
study, we have analyzed several oxidative stress markers that could be affected by propo-
fol Lipuro infusion and observed a significant decrease for lipid peroxides, carbonyls and 
hydroperoxides, which are the oxidative markers that are usually elevated as a result of 
toxic effect of drugs (Evans et al. 2002). The decrease observed in these parameters for 
this propofol formulation might be due to the antioxidative nature of propofol which 
could also contribute to the effects observed in the antioxidant enzymes (SOD, CAT and 
GPx) as already seen by Ranjbar et al. (2014). Regarding the SMOFlipid group, we found 
differences in protein carbonyls oxidation compared to the control group which can lead 
to changes in the physical properties of the proteins and consequently to the organ func-
tion and recent clinical studies have linked soybean-oil lipid emulsions to the occurrence 
of cholestasis (Kaffe et al. 2015). In fact, it was also showed that accumulation of free 
radicals in cholestatic liver disease induces carbonylated protein increments (Sokolovic 
et al. 2013) and thus, we hypothesize that SMOFlipid emulsion can result in this condi-
tion, especially in patients with associated liver impairment.
In conclusion, at the measured concentrations (2.98 ± 0.69 μg g−1) in the liver, propo-
fol Lipuro formulation evidenced to have higher antioxidant activity and lower impair-
ment of the mitochondrial function comparatively to the improved lipid formulation, 
SMOFlipid, using the rabbit as animal model, however, it also has collateral cardiorespi-
ratory effects, by diminishing the metabolic rate, blood perfusion and oxygen delivery to 
the brain and vital organs which is consistent with the high propofol dose quantified in 
blood (52.08 ± 15.65 μg mL−1). As a final point, long-term high doses infusion of propo-
fol Lipuro emulsion for sedation prompted changes in clinical and hemodynamic signs, 
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particularly hypotension and bradycardia, blood gas levels and many blood biomarkers, 
as CK and serum lipids, liver and kidney parameters. At the end of the experiment, the 
animals under propofol Lipuro anesthesia showed also several organ failures that were 
compatible with PRIS. Many similar variations in blood biomarkers and multi-organ 
deterioration were observed in animals receiving the SMOFlipid (lipid emulsion) with-
out the propofol on it. Mitochondrial bioenergetics results from this, long-term high 
dose infusion protocol of propofol Lipuro, indicate that mitochondria may not be the 
main and unique trigger compound of PRIS but we cannot exclude its involvement of 
other pathways in liver failure such as cell death via apoptosis and necrosis which were 
not addressed in this work. The contribution of hypotension and hypoperfusion for the 
final results cannot be discarded. Moreover, lipid emulsions may also play a role in the 
initial installation of the syndrome. We strongly recommend the close monitoring not 
only of patients and animals undergoing propofol Lipuro lipid-based prolonged seda-
tion, but also receiving improved lipid emulsions as SMOFlipid for prolonged parenteral 
nutrition. These results may provide new strategies and approaches for the insight of the 
biochemical mechanisms underlying PRIS, using the rabbit as a translational model.
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